{"entity":{"id":"onc-ai","kind":"company","name":"Onc.AI","aka":[],"tldr":"Onc.AI trains artificial intelligence on routine CT scans to predict early whether a lung cancer patient's immunotherapy is working, so doctors and drug developers can change course sooner.","summary":"Onc.AI develops deep learning radiomics models trained on a large oncology real world dataset. Its Serial CT Response Score analyses sequential CT scans to assess response to immunotherapy in non small cell lung cancer earlier than RECIST based reads and received FDA Breakthrough Device Designation in February 2025. Products are Onclara IO, which predicts response and outcomes for metastatic lung cancer patients starting immunotherapy, and Onclara Evaluate for go or no go decisions in phase 1b and 2 trials; all remain investigational. Validation has been presented at AACR 2025 (with GSK) and ASCO 2025 and 2026 on Flatiron Health data. Onc.AI operates from the San Francisco Bay Area and Waterloo, Ontario. It raised a USD 6 million seed in November 2020 and a USD 25 million Series A in January 2023, received a USD 2 million NCI SBIR grant in 2024, and names MassMutual and GSK among its investors.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://onc.ai"},{"label":"Series A announcement page","url":"https://onc.ai/25mm-series-a-financing/"},{"label":"Seed announcement page","url":"https://onc.ai/6mm-series-seed-financing/"},{"label":"Press releases index","url":"https://onc.ai/category/press-releases/"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["ai-computation","imaging","immunotherapy"],"technologies":["ct","checkpoint-inhibitor"],"targets":["pd1","pdl1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The seed and Series A pages carry only a headline; dates were taken from the WordPress post metadata (2020-11-05 and 2023-01-01) and investor names (MassMutual, GSK) from the company homepage. HQ given as 'SF Bay Area' on the site, recorded as San Francisco. Founding year not sourced. FDA Breakthrough designation date is from the homepage summary; the dedicated page did not render text."],"hq":"San Francisco, CA","country":"US","companyType":"ai-software","website":"https://onc.ai","stage":"startup","investors":[],"funding":[{"round":"Seed","year":2020,"amountUsd":6000000,"source":"https://onc.ai/6mm-series-seed-financing/","note":"Company page dated November 2020; investors not named on the page"},{"round":"Series A","year":2023,"amountUsd":25000000,"source":"https://onc.ai/25mm-series-a-financing/","note":"Company page dated January 2023; investors not named on the page"},{"round":"Grant","year":2024,"amountUsd":2000000,"source":"https://onc.ai/","note":"National Cancer Institute SBIR grant, per company website"}]},"route":"/companies/onc-ai/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"},{"id":"imaging","kind":"section","name":"Imaging","route":"/fronts/imaging/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"ct","kind":"technology","name":"CT (computed tomography)","route":"/technologies/ct/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}]}}